|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RRAGC |
Gene summary for RRAGC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RRAGC | Gene ID | 64121 |
| Gene name | Ras related GTP binding C | |
| Gene Alias | GTR2 | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | B4DQ03 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64121 | RRAGC | LZE2T | Human | Esophagus | ESCC | 1.24e-02 | 2.36e-01 | 0.082 |
| 64121 | RRAGC | LZE4T | Human | Esophagus | ESCC | 1.30e-07 | 3.12e-02 | 0.0811 |
| 64121 | RRAGC | LZE8T | Human | Esophagus | ESCC | 3.22e-05 | -7.41e-02 | 0.067 |
| 64121 | RRAGC | LZE22T | Human | Esophagus | ESCC | 2.37e-02 | 2.60e-01 | 0.068 |
| 64121 | RRAGC | LZE24T | Human | Esophagus | ESCC | 1.73e-15 | 3.42e-01 | 0.0596 |
| 64121 | RRAGC | LZE21T | Human | Esophagus | ESCC | 1.28e-02 | 2.38e-02 | 0.0655 |
| 64121 | RRAGC | P1T-E | Human | Esophagus | ESCC | 3.51e-05 | 1.01e-01 | 0.0875 |
| 64121 | RRAGC | P2T-E | Human | Esophagus | ESCC | 8.22e-24 | 4.66e-01 | 0.1177 |
| 64121 | RRAGC | P4T-E | Human | Esophagus | ESCC | 2.24e-16 | 4.04e-01 | 0.1323 |
| 64121 | RRAGC | P5T-E | Human | Esophagus | ESCC | 1.23e-17 | 3.32e-01 | 0.1327 |
| 64121 | RRAGC | P8T-E | Human | Esophagus | ESCC | 2.58e-19 | 1.58e-01 | 0.0889 |
| 64121 | RRAGC | P9T-E | Human | Esophagus | ESCC | 2.20e-11 | 6.64e-02 | 0.1131 |
| 64121 | RRAGC | P10T-E | Human | Esophagus | ESCC | 1.19e-18 | 2.93e-01 | 0.116 |
| 64121 | RRAGC | P11T-E | Human | Esophagus | ESCC | 2.37e-04 | 2.85e-01 | 0.1426 |
| 64121 | RRAGC | P12T-E | Human | Esophagus | ESCC | 1.10e-16 | 1.39e-01 | 0.1122 |
| 64121 | RRAGC | P15T-E | Human | Esophagus | ESCC | 1.27e-17 | 3.61e-01 | 0.1149 |
| 64121 | RRAGC | P16T-E | Human | Esophagus | ESCC | 3.49e-21 | 6.59e-02 | 0.1153 |
| 64121 | RRAGC | P17T-E | Human | Esophagus | ESCC | 2.52e-04 | 1.57e-01 | 0.1278 |
| 64121 | RRAGC | P19T-E | Human | Esophagus | ESCC | 1.21e-04 | 2.04e-01 | 0.1662 |
| 64121 | RRAGC | P20T-E | Human | Esophagus | ESCC | 5.03e-15 | 2.63e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
| GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
| GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
| GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:19909284 | Esophagus | ESCC | response to amino acid starvation | 37/8552 | 49/18723 | 2.05e-05 | 1.78e-04 | 37 |
| GO:00432007 | Esophagus | ESCC | response to amino acid | 74/8552 | 116/18723 | 6.23e-05 | 4.76e-04 | 74 |
| GO:000110110 | Esophagus | ESCC | response to acid chemical | 84/8552 | 135/18723 | 7.70e-05 | 5.74e-04 | 84 |
| GO:00319294 | Esophagus | ESCC | TOR signaling | 79/8552 | 126/18723 | 8.57e-05 | 6.21e-04 | 79 |
| GO:00341984 | Esophagus | ESCC | cellular response to amino acid starvation | 34/8552 | 46/18723 | 9.39e-05 | 6.70e-04 | 34 |
| GO:00712305 | Esophagus | ESCC | cellular response to amino acid stimulus | 48/8552 | 71/18723 | 1.55e-04 | 1.03e-03 | 48 |
| GO:00712296 | Esophagus | ESCC | cellular response to acid chemical | 52/8552 | 80/18723 | 3.79e-04 | 2.20e-03 | 52 |
| GO:00320061 | Esophagus | ESCC | regulation of TOR signaling | 63/8552 | 104/18723 | 1.55e-03 | 7.29e-03 | 63 |
| GO:00320082 | Esophagus | ESCC | positive regulation of TOR signaling | 31/8552 | 47/18723 | 4.01e-03 | 1.62e-02 | 31 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:001050611 | Liver | Cirrhotic | regulation of autophagy | 132/4634 | 317/18723 | 2.17e-11 | 1.33e-09 | 132 |
| GO:004259412 | Liver | Cirrhotic | response to starvation | 87/4634 | 197/18723 | 1.85e-09 | 7.78e-08 | 87 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0414015 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0513122 | Liver | Cirrhotic | Shigellosis | 105/2530 | 247/8465 | 1.31e-05 | 1.21e-04 | 7.48e-05 | 105 |
| hsa041406 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa0513132 | Liver | Cirrhotic | Shigellosis | 105/2530 | 247/8465 | 1.31e-05 | 1.21e-04 | 7.48e-05 | 105 |
| hsa0414011 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa0414021 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0414031 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa0513152 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa041409 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| hsa0513130 | Oral cavity | OSCC | Shigellosis | 150/3704 | 247/8465 | 3.96e-08 | 3.12e-07 | 1.59e-07 | 150 |
| hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
| hsa0414014 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RRAGC | SNV | Missense_Mutation | c.998N>G | p.Lys333Arg | p.K333R | Q9HB90 | protein_coding | tolerated(0.71) | benign(0.005) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| RRAGC | insertion | Nonsense_Mutation | novel | c.1146_1147insTAATTTT | p.Ala383Ter | p.A383* | Q9HB90 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| RRAGC | insertion | In_Frame_Ins | novel | c.1144_1145insTAATATCTCAATATAGAATGCTGGAGGTATTTGGGA | p.Thr381_Ser382insIleIleSerGlnTyrArgMetLeuGluValPheGly | p.T381_S382insIISQYRMLEVFG | Q9HB90 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| RRAGC | SNV | Missense_Mutation | novel | c.125G>C | p.Gly42Ala | p.G42A | Q9HB90 | protein_coding | tolerated(0.86) | benign(0.01) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RRAGC | SNV | Missense_Mutation | c.1187G>A | p.Arg396Gln | p.R396Q | Q9HB90 | protein_coding | deleterious_low_confidence(0.04) | benign(0.009) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RRAGC | SNV | Missense_Mutation | novel | c.99N>T | p.Glu33Asp | p.E33D | Q9HB90 | protein_coding | tolerated(0.65) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| RRAGC | SNV | Missense_Mutation | novel | c.373G>T | p.Asp125Tyr | p.D125Y | Q9HB90 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RRAGC | SNV | Missense_Mutation | novel | c.913N>A | p.Gly305Arg | p.G305R | Q9HB90 | protein_coding | tolerated(0.32) | benign(0.024) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RRAGC | SNV | Missense_Mutation | novel | c.868G>A | p.Asp290Asn | p.D290N | Q9HB90 | protein_coding | deleterious(0) | possibly_damaging(0.777) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| RRAGC | SNV | Missense_Mutation | c.605A>G | p.Asp202Gly | p.D202G | Q9HB90 | protein_coding | deleterious(0) | benign(0.073) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |